<!DOCTYPE  html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"/><title>11 Gastrointestinal stromal tumours</title><link href="navigation.css" rel="stylesheet" type="text/css"/><link href="document.css" rel="stylesheet" type="text/css"/></head><body><p class="top_nav"><a href="part16.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part18.htm">Далее &gt;</a></p><p style="padding-top: 3pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark16" class="s95" name="bookmark53">Chapter 11</a><a name="bookmark54">&zwnj;</a></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-left: 49pt;text-indent: 0pt;line-height: 1pt;text-align: left;"><span><img width="374" height="1" alt="image" src="Image_168.png"/></span></p><p style="padding-top: 4pt;padding-left: 49pt;text-indent: 0pt;text-align: left;"><a href="part5.htm#bookmark16" class="h2">Gastrointestinal stromal </a><h2 href="#bookmark16">tumours</h2></p><p class="s5" style="padding-top: 10pt;padding-left: 48pt;text-indent: 0pt;text-align: left;">haesun Choi</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-top: 13pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.1 <span class="h4">Introduction</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Gastrointestinal stromal tumour (GIST) accounts for only 0.2% of all gastrointestinal (GI) neoplasm but is the most common tumour of non-epithelial origin in the GI tract. The term <i>gastrointestinal stromal tumour </i>was first used by Mazur and Clark<span class="s22">1 </span>to describe an unusual type of non-epithelial GI tumour that lacked the traditional features of smooth muscle or Schwann cells. GISTs are now thought to derive from a precursor of the interstitial cells of Cajal, which are normally present in the myenteric plexus, and are clearly distinct from other mesenchymal tumours, such as leiomyomas and leiomyosarcomas.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The true incidence rate of GISTs in all population is not known. The reported population-based incidence rates vary from 6.5 to 14.5 per million. Assuming the an- nual incidence rate of 10 per million, approximately 3000 cases might be diagnosed in the USA a year. The median age at diagnosis is 66–69 years.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">11.2 <span class="h4">Clinical presentation</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">GISTs can occur anywhere along the GI tract and is associated with a broad range of clinical presentations. In adult GISTs, the stomach (60%) and small intestine (30%) are the most common primary sites and the duodenum the third (5%). Oesophageal and colorectal GISTs are rare. On rare occasions GISTs occurs in the mesentery, omentum, or retroperitoneum. Extragastrointestinal (soft tissue) stromal tumours are histologically and immunophenotypically similar to their gastrointestinal counterpart, but have an aggressive course similar to small intestinal rather than gastric stromal tumours.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The tumours are often large at the time of initial presentation but bowel obstruction is rare due to its exophytic nature of growth. In a population-based study, the median tumour size of GISTs that were detected based on symptoms, incidental findings, or during an autopsy were 8.9, 2.7, and 3.4 cm, respectively. Small GISTs (smaller than 2 cm) usually do not produce symptoms and are detected incidentally during abdom- inal exploration, endoscopy, or radiologic imaging. Symptoms are often non-specific, including, early satiety, vague abdominal pain or dyspepsia, and palpable mass. It is not infrequent for the patient to present at the emergency room with an acute abdomen (GI bleeding, perforation, intraperitoneal bleeding due to tumour rupture, and, rarely, gastrointestinal obstruction). Nearly 50% of patients present with metastasis. Most</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">common sites of metastasis are liver and peritoneal cavity. Unlike GI adenocarcin- omas, lymph node metastasis is extremely uncommon. Less frequently, the metastasis can be found in the lungs, pleura, and soft tissue.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">11.3 <span class="h4">Diagnosis</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">11.3.1 <span class="s29">Imaging studies</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Imaging is important not only for diagnosing and staging the tumours, but also for monitoring the tumours during and following treatments. Computed tomography (CT) is currently the modality of choice for these purposes, although other imaging techniques, such as fluorine-18-fluorodeoxyglucose (FDG) positron emission tomog- raphy (PET), magnetic resonance (MR) imaging, and ultrasonography, can also be used.<span class="s22">2 </span>Further detail is discussed in a separate section in this chapter.</p><p class="s97" style="padding-top: 10pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">11.3.2 <span class="s29">Pathology</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The tumours are highly vascular, submucosal in location (Figure 11.1), and grow out away from the originating bowel lumen but may form polypoid masses. Mucosal ul- ceration is not uncommon in large tumours that are often associated with GI bleeding. Most GISTs present as a single, well-circumscribed nodule.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">A core biopsy is recommended for an adequate tissue sampling, although obtaining adequate tumour tissue material for definitive diagnosis before surgical resection can be challenging because these tumours tend to be soft and friable with a risk of rup- ture. A biopsy may not be necessary if the tumour is suspected and is easily resectable without preoperative therapy on CT.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="408" height="180" alt="image" src="Image_169.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: justify;">Fig. 11.1 <span class="s52">Typical submucosal presentation of gisT seen on endoscopy and endoscopic ultrasound. (a) Typical appearances of a submucosal bilobulated gisT of the stomach. note the intact mucosa. endoscopic biopsies were expectedly, unremarkable.</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">(b) endoscopic us appearances of a typical gisT. a 2.5 cm, heterogeneous gisT arises from the first submucosal layer (large arrow), and contains an anechoic space suggesting central necrosis. note the normal intact mucosa (small arrows).</p><p class="s97" style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.3.3 <span class="s29">Prognostic features</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Based on previously published series of GISTs, the two most important prognostic features of a primary tumour are the size and mitotic index. Smaller studies indicate that anatomic location affects the risk of disease recurrence and progression. Small intestinal GISTs are more aggressive than gastric GISTs of equal size, and this should be factored into the risk assessment of a primary tumour. Based on the summary in Table 11.1<span class="s22">3 </span>GISTs that are 2 cm or less in size can be regarded as essentially benign, but lesions larger than 2 cm have a risk of recurrence.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">11.4 <span class="h4">Treatment</span></p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The optimal management of GIST requires a multidisciplinary approach. The re- markable efficacy of imatinib mesylate (Gleevec; Norvatis, Basel, Switzerland), a tyrosine kinase inhibitor, has revolutionized the management approach for GIST. Imatinib mesylate, a phenylaminopyrimidine derivative, is a small molecule that is known to inhibit the specific kinase action of Abl and the chimeric BCR-Abl fu- sion protein. Approximately 4% of patients with GIST are intolerant of imatinib. Furthermore, 50% of patients will eventually develop resistance to imatinib at a median of 24 months, commonly (70%) the result of secondary mutations in spe- cific <i>KIT </i>loci. New second-line targeted agents are now also available for those with imatinib-resistant GISTs.<span class="s22">4</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s24" style="padding-left: 5pt;text-indent: 0pt;text-align: justify;">Table 11.1 <span class="s52">risk stratification of primary gisT by mitotic index, size, and site</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><table style="border-collapse:collapse;margin-left:5.6929pt" cellspacing="0"><tr style="height:24pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;line-height: 112%;text-align: left;">Tumour parameters</p></td><td style="width:273pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9" colspan="5"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Risk of progressive disease * (%)</p></td></tr><tr style="height:14pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;text-indent: 0pt;text-align: left;">Mitotic index</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Size</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Gastric</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Duodenum</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Jejunum/ileum</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s26" style="padding-top: 1pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Rectum</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">≤5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">≤2 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">none (0%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">none (0%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">none (0%)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">none (0%)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">≤5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;2 ≤ 5 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Very low (1.9%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">low (4.3%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">low (8.3%)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">low (8.5%)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">≤5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;5 ≤ 10 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">low (3.6%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Moderate (24%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">(insuff. data)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">(insuff. data)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">≤5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;10 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Moderate (10%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (52%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (34%)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (57%)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">&gt;5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">≤2 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">none+</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high+</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">(insuff. data)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (54%)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">&gt;5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;2 ≤5 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">Moderate (16%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (73%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (50%)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (52%)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">&gt;5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;5 ≤10 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (55%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (85%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">(insuff. data)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">(insuff. data)</p></td></tr><tr style="height:15pt"><td style="width:50pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;text-indent: 0pt;text-align: left;">&gt;5 per 50 hpf</p></td><td style="width:45pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">&gt;10 cm</p></td><td style="width:61pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (90%)</p></td><td style="width:62pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (90%)</p></td><td style="width:56pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (86%)</p></td><td style="width:49pt;border-top-style:solid;border-top-width:1pt;border-top-color:#9B95C9;border-bottom-style:solid;border-bottom-width:1pt;border-bottom-color:#9B95C9"><p class="s99" style="padding-top: 2pt;padding-left: 2pt;text-indent: 0pt;text-align: left;">high (71%)</p></td></tr></table><p class="s14" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">gisT—gastrointestinal stromal tumour, hpf—high power field, insuff—insufficient.</p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">*Defined as metastatsis or tumour-related death.</p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">+Denotes small numbers of cases.</p><p class="s14" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 109%;text-align: left;">reproduced with permission from Demetri gD et al. ‘nCCn Task Force report: management of patients with gastrointestinal stromal tumor (gisT)--update of the nCCn clinical practice guidelines’. J natl Compr Canc netw. Vol. 5, suppl 2, pp. s1–29. Copyright © 2007 national Comprehensive Cancer network.</p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The tumours less than 2 cm found incidentally can be monitored using endoscopy or a cross-sectional imaging. In patients with the localized, potentially resectable tu- mours without significant risk of comorbidity, surgical resection is the choice. For those with comorbidity, the US national comprehensive cancer network (NCCN) guideline recommends neoadjuvant imatinib along with appropriate imaging work-up prior to and during the course of treatment until surgical resection is feasible (usually in 3–6 months). For those unresectable, recurrent, or metastatic GISTs, imatinib is the initial treatment of choice. The imatinib is also recommended in post-surgical patients with a high risk of recurrence, such as resection with margin positive.<span class="s22">5</span></p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">For those undergoing systemic treatment, image assessment is critical to evaluate the tumour response (see later) to explore further treatment options without delay when needed. Those who develop resistance to imatinib may be overcome by increasing the imatinib dose from 400 to 800 mg/day, typically in those tumours with muta- tions in <i>KIT </i>exon 9.<span class="s22">6 </span>While focal resistance may be controlled transiently, by surgical removal of the resistant lesion, there is a general consensus that multifocal imatinib resistance should be treated with an alternative targeted agent, such as sunitinib malate (SUTENT®, Pfizer Inc., CA, USA). Sunitinib is an oral multitargeted RTK inhibitor of KIT, PDGFR-α and -β, VEGF receptors (VEGFR-1, -2, and -3), FMS-like tyrosine kinase 3, colony-stimulating factor 1 receptor, and glial cell line-derived neurotrophic factor receptor (rearranged during transfection). Sunitinib is effective in imatinib- refractory patients, including those with the <i>KIT </i>exon 9 mutation, at the standard daily dose of 50 mg/day (schedule 4/2).</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">11.5 <span class="h4">Imaging</span></p><p class="s97" style="padding-top: 6pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">11.5.1 <span class="s29">Computed tomographic imaging</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In patients with biopsy-proven GISTs, computed (CT) is the imaging modality of choice at initial presentation, for staging, and for monitoring the disease during its course. When a submucosal tumour is found incidentally during endoscopy (Figure 11.1), the extraluminal extent of disease should be evaluated with CT.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Typically, CT images of the abdomen and pelvis are acquired prior to and following bolus administration (usually 3–5 cc/sec of injection rate) of an iodinated intravenous contrast agent and oral and rectal contrast agents. For contrast-enhanced CT, arterial- and portal-venous-phase images (obtained using a biphasic or triphasic technique) are required to optimize the detection and characterization of the hepatic metastasis or hypervascular masses, such as GISTs.</p><p style="padding-left: 11pt;text-indent: 8pt;line-height: 94%;text-align: justify;">The CT features of GISTs can vary depending on the size, location, and aggressive- ness of tumour. They are typically highly vascular enhancing masses, submucosal in location, growing away from the original bowel lumen. The tumours can be heteroge- neous and predominantly hypodense when they become necrotic, haemorrhagic, or myxoid degenerating. The primary GIST can occasionally present with an ulceration and a fistula to the originating bowel lumen. Air or oral contrast agent may be seen within the fistularized mass on the CT images. At the time of presentation, the mass</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="341" height="258" alt="image" src="Image_170.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">Fig. 11.2 <span class="s52">(a) polypoid gastric gisT (arrow), (b) exophytic gastric gisT (arrow),</span></p><p class="s52" style="padding-top: 1pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">(c) exophytic small bowel gisT (arrow) with a fistulous tract. note the contrast (small arrows) within the tumour cavity. s: stomach; sB: small bowel.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">is often large and may be difficult to identify its origin. Despite the large size, clinical evidence of GI obstruction is uncommon (Figure 11.2).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Most common metastasis are to the liver and peritoneal cavity which can be readily identified on CT. Metastasis in the pleura, lungs, or soft tissues, such as abdominal wall, can occur less frequently. Lymph node metastases are rare. These metastatic lesions have CT features similar to those of the primary tumours: they may be (depending on the tumour size) homogeneously to heterogeneously enhancing soft-tissue masses, often with tumour vessels visible.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.5.2 <span class="s29">Positron emission tomography</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">The primary role for positron emission tomography (PET) in the initial evaluation of biopsy-proven GISTs is in staging (Figure 11.3). Baseline FDG-PET is recommended in patients in whom FDG-PET will be used to monitor therapy or who require a very short follow-up (2–3 weeks), such as those with marginally resectable GIST.<span class="s22">3</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">In general, for tumours less than 1 cm in size, FDG-PET may not be reliable in identifying metabolically active lesions.<span class="s22">2 </span>In GIST, it has been reported that the overall sensitivity of FDG-PET is approximately 80% in detection at initial presentation; pa- tients with negative uptake on pretreatment FDG-PET had tumours ranging from 1.0 to 4.7 cm. Similarly, Hersh et al. found negative results on pretreatment FDG-PET in four of eight patients. These four patients had homogeneous tumours on CT images, with a mean diameter of 6 cm (range 3–8 cm).<span class="s22">7</span></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="382" height="430" alt="image" src="Image_171.gif"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 113%;text-align: left;">Fig. 11.3 <span class="s52">responding gastrointestinal stromal tumour in a 59-year-old woman with recurrent gastric gisT in the omentum. (a, b) pretreatment contrast-enhanced CT scan</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">(a) shows a large, enhancing omental mass (arrow) abutting the anterior surface of the stomach corresponding to the mass (arrow) with markedly increased glucose update shown on pre-treatment FDg-peT (B). (c, d) Contrast-enhanced CT scan (c) obtained two months after treatment showed that the mass (arrow) has decreased in size and become homogeneous, with a marked decrease in CT density corresponding to the mass (arrow) with no appreciable glucose uptake shown on FDg-peT (d) obtained at the same time.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s97" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">11.5.3 <span class="s29">Ultrasound</span></p><p style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Endoscopic ultrasonography (EUS) may be used in evaluating small (&lt;2 cm) GISTs that are incidentally found during endoscopy. The high-frequency probe (12–30 MHz) used in EUS can delineate each layer of bowel wall and, therefore, may reliably locate tumour origin within or outside of the wall. EUS also can evaluate the tumour vascu- larity when used in conjunction with Doppler ultrasonography. EUS is most useful in the oesophagus, stomach, duodenum, and anorectum. EUS is, however, not a routine</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">imaging modality because of its limited penetration and field of view, and CT should always be performed to accurately estimate the extent of disease.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Although transabdominal ultrasonography may be used to evaluate hepatic metas- tasis, this technique is inappropriate for evaluating the peritoneal cavity or large tu- mours in staging or monitoring the disease following treatment.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.5.4 <span class="s29">Magnetic resonance imaging</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Well-performed magnetic resonance imaging (MRI) is superior to contrast-enhanced CT in evaluating hepatic metastasis and rectal GIST with superior soft-tissue con- trast and direct multiplanar acquisition capability. However, MRI is not the primary imaging modality of choice in evaluating GIST patients because of its limited sensi- tivity in detecting peritoneal tumours.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">On MR images, GISTs are generally well defined; the solid portions of the masses are typically of low to intermediate signal intensity on T1-weighted images and high signal intensity on T2-weighted images. As in CT, the tumours enhance after admin- istration of an intravenous contrast agent.<span class="s22">8 </span>Intravenous contrast helps to delineate vi- able solid components and non-enhanced necrotic areas. Internal haemorrhage may have signal intensity varying from high to low on both T1- and T2-weighted images, depending on the time from the haemorrhage.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s96" style="padding-left: 5pt;text-indent: 0pt;text-align: left;">11.6 <span class="h4">Response evaluation and surveillance</span></p><p class="s97" style="padding-top: 6pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.6.1 <span class="s29">Response evaluation</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">In patients who have undergone surgical resection of GISTs, CT scan every 3– 6 months is performed for surveillance of metastatic or recurrent disease. In patients with unresectable advanced disease or metastasis, CT is recommended within three months of the start of systemic treatment.<span class="s22">5</span></p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Responding GISTs are characterized by a dramatic change in the pattern of en- hancement on contrast-enhanced CT images, from heterogeneous hyperattenuation to homogeneous hypoattenuation, accompanying the resolution of enhancing tumour nodules and a decrease in tumour vessels, regardless of whether the tumour size de- creases (Figures 11.3, 11.4). These changes can be observed within one or two months and may be seen as early as one week after treatment (unpublished data).</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Traditional size-based response evaluation criteria, such as the Response Evaluation Criteria in Solid Tumours (RECIST) or World Health Organization criteria, under- estimate the response of the GIST treated with targeted agents. The median time to evidence of tumour shrinkage on CT is about 3–4 months, although it sometimes may take 6–12 months or longer. More importantly, responding GISTs sometimes increase in size because of intratumoural haemorrhage, necrosis, or myxoid degeneration (Figure 11.4).<span class="s22">9 </span>In these cases, observation of changes in tumour density (indicating a decrease in density) and in the enhancement pattern (indicating a decrease in tumour vasculature) aid to reaching the correct conclusion. New CT response evaluation cri- teria have been advocated.<span class="s22">10–12 </span>A 10% decrease in the sum of the uni-dimensional tu- mour size or a 15% decrease in tumour density, as determined by the CT attenuation</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="382" height="287" alt="image" src="Image_172.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(d)</p><p class="s24" style="padding-top: 3pt;padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 11.4 <span class="s52">responding hepatic metastasis with pseudoprogression in a 56-year-old male with duodenal gisT. (a) pre-treatment contrast-enhanced CT showed an enhancing hepatic metastasis (arrow) in segment seven with the tumour density measured 40 hu. note the peripheral enhancing component (small arrows). (b) Contrast-enhanced CT image obtained at two months after treatment demonstrated a minimal decrease in size of the hepatic metastases (arrow) but with a significant decrease in CT density</span></p><p class="s52" style="padding-left: 11pt;text-indent: 0pt;line-height: 114%;text-align: left;">(27 hu). The peripheral enhancement is no longer evident. This is typical of responding gisT. Contrast-enhanced CT image (c) obtained seven months after treatment showed a homogenously hypoattenuating tumour with a continuous decrease in tumour density (18 hu). notice the significant increase in tumour size with no appreciable glucose uptake on FDg-peT image (d). The enlarging homogenous tumour with a continuous decrease in tumour density should not be confused with a progressing tumour.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="padding-top: 5pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">coefficient in Hounsfield units, at the first follow-up (two months) following treat- ment can best separate the good responders and poor responders and response at this time is an excellent predictor of progression-free survival.<span class="s22">10,11 </span>The same authors pro- posed modified CT response criteria (Table 11.1) using both tumour density and uni- dimensional measurement of tumour size, of which reproducibility was confirmed in an extended group of patients. Similar results are reported using the sum of products of bi-dimensional measurement (BDM)<span class="s22">12 </span>with a 8.25% decrease in tumour size at one month following treatment best identifying the group of patients in whom treatment failed. It was concluded that stability or any decrease in the sum of products of bi- dimensional measurement at one month following treatment was a strong indicator of time-to-treatment failure in 52 patients. Perfusion CT and PET/CT in GIST patients before and after treatment with imatinib mesylate at three, five, or seven days found that PET responders (&gt;30% decrease in SUV) had decreases in both blood flow and</p><p style="padding-top: 4pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">blood volume to tumours, while non-responders had an increase in blood flow and less increase in blood volume.<span class="s22">13 </span>Use of perfusion CT requires special post-processing software, careful monitoring of data acquisition, and data analysis for reducibility.</p><p class="s97" style="padding-top: 10pt;padding-left: 5pt;text-indent: 0pt;text-align: left;">11.6.2 <span class="s29">Surveillance</span></p><p style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 94%;text-align: justify;">Contrast-enhanced CT plays an important role in surveillance and the early detection of tumour recurrence or progression that might signal the clonal emergence of resist- ance to ongoing targeted treatment.</p><p style="padding-left: 5pt;text-indent: 8pt;line-height: 94%;text-align: justify;">Recurrence or disease progression is traditionally diagnosed by finding an increase in tumour size or the development of new lesions at the site of previous disease or distant metastasis. However, as mentioned previously, increased tumour size alone, without a change in tumour enhancement or tumour vessels, may not accurately rep- resent the disease progression. Development of an intratumoural enhancing nodule is often the earliest sign of disease progression. This is observed within a treated hypodense tumour without a change in tumour size (Figure 11.5). Thorough analysis of each treated lesion is required to identify these new intratumoural nodules. If tu- mour recurrence or disease progression is suspected, short-term follow-up (e.g. one month) using well-designed, contrast-enhanced CT imaging may be performed for confirmative diagnosis. Whenever the CT findings are inconclusive or inconsistent with clinical findings, FDG-PET is indicated.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p style="text-indent: 0pt;text-align: left;"><span><img width="333" height="252" alt="image" src="Image_173.png"/></span></p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(a)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(b)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p style="text-indent: 0pt;text-align: left;"/><p class="s30" style="text-indent: 0pt;line-height: 9pt;text-align: left;">(c)</p><p class="s24" style="padding-top: 3pt;padding-left: 5pt;text-indent: 0pt;line-height: 114%;text-align: left;">Fig. 11.5 <span class="s52">recurrent gisT with an enlarging intratumoral nodule. (a) Contrast-enhanced CT obtained at nine months after treatment showed a typical responding gisT (arrow). (pretreatment CT is not shown here). (b, c) note a tiny enhancing nodule (arrows) developed within the treated tumour at ten months after treatment (b), with an increase in size 11 months later (c).</span></p><p class="s96" style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;text-align: left;">11.7 <span class="h4">Conclusion</span></p><p style="padding-top: 4pt;padding-left: 11pt;text-indent: 0pt;line-height: 94%;text-align: justify;">GIST is a mesenchymal tumour of the GI tract. It often used to be misdiagnosed as leiomyomas and leiomyosarcomas without optimal therapeutic options until KIT re- ceptor protein was identified in the tumour cells. Correct diagnosis is critical to take advantage of the early targeted agents, KIT tyrosine kinase receptor inhibitor, such as imatinib, with dramatic improvement of the survival. Its unique immunohistochemical profile and mutational analysis of the kinase genes <i>KIT </i>and platelet-derived growth factor receptor alpha (<i>PDGFRA) </i>help to make a correct diagnosis. Understanding the unique imaging features has become important not only at the time of initial presenta- tion but also during the time of response evaluation to the targeted agents.</p><p style="text-indent: 0pt;text-align: left;"><br/></p><p class="s73" style="padding-left: 11pt;text-indent: 0pt;text-align: left;">References</p><p class="s74" style="padding-top: 5pt;padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">1. <b>Mazur MT</b>, <b>Clark HB </b>(1983). Gastric stromal tumours. Reappraisal of histogenesis.</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>American Journal Surgeical Pathology</i>, <b>7</b>(6): 507–519.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">2. <b>Choi H</b>, <b>Charnsangavej C</b>, <b>de Castro Faria S, et al. </b>(2004). CT evaluation of the response of gastrointestinal stromal tumours after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. <i>American Journal of Roentgenology</i>,</p><p class="s75" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">183<span class="s74">(6): 1619–1628.</span></p><p class="s74" style="padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">3. <b>Demetri GD</b>, <b>Benjamin RS</b>, <b>Blanke CD, et al. </b>(2007). NCCN Task Force</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;text-align: left;">report: management of patients with gastrointestinal stromal tumour (GIST)—update of the NCCN clinical practice guidelines. <i>Journal of National Comprehensive Cancer Network</i>, <b>5</b>(2): S1–29; quiz S30.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">4. <b>Demetri GD</b>, <b>van Oosterom AT</b>, <b>Garrett CR, et al. </b>(2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet</i>, <b>368</b>(9544): 1329–1338.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">5. <b>Network NCC (2018)</b>. <i>NCCN Guidelines Version 1.2018 Gastrointestinal Stromal Tumours (GIST)</i>. Fort Washington, PA: NCCN.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">6. <b>Debiec-Rychter M</b>, <b>Sciot R</b>, <b>Le Cesne A, et al. </b>(2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i>, <b>42</b>(8): 1093–1103.</p><p class="s74" style="padding-top: 1pt;padding-left: 16pt;text-indent: 0pt;line-height: 11pt;text-align: left;">7. <b>Hersh MR</b>, <b>Choi J</b>, <b>Garrett C</b>, <b>Clark R </b>(2005). Imaging gastrointestinal stromal tumours.</p><p class="s74" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;"><i>Cancer Control</i>, <b>12</b>(2): 111–115.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">8. <b>Levy AD</b>, <b>Remotti HE</b>, <b>Thompson WM</b>, <b>Sobin LH</b>, <b>Miettinen M </b>(2003). Gastrointestinal stromal tumours: radiologic features with pathologic correlation. <i>Radiographics</i>,</p><p class="s75" style="padding-left: 25pt;text-indent: 0pt;line-height: 11pt;text-align: left;">23<span class="s74">(2): 283–304, 456; quiz 532.</span></p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -9pt;text-align: left;">9. <b>Hong X</b>, <b>Choi H</b>, <b>Loyer EM</b>, <b>Benjamin RS</b>, <b>Trent JC</b>, <b>Charnsangavej C </b>(2006). Gastrointestinal stromal tumour: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. <i>Radiographics</i>, <b>26</b>(2): 481–495.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">10. <b>Benjamin RS</b>, <b>Choi H</b>, <b>Macapinlac HA, et al. </b>(2007). We should desist using RECIST, at least in GIST. <i>Journal of Clinical Oncology</i>, <b>25</b>(13): 1760–1764.</p><p class="s74" style="padding-top: 1pt;padding-left: 25pt;text-indent: -13pt;text-align: left;">11. <b>Choi H</b>, <b>Charnsangavej C</b>, <b>Faria SC, et al. </b>(2007). Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumour treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. <i>Journal of Clinical Oncology</i>, <b>25</b>(13): 1753–1759.</p><p class="s74" style="padding-top: 4pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">12. <b>Holdsworth CH</b>, <b>Manola J</b>, <b>Badawi RD, et al. </b>(2004). Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumours (GIST). <i>Journal of Clinical Oncology</i>, <b>22</b>(14): 197s.</p><p class="s74" style="padding-top: 1pt;padding-left: 20pt;text-indent: -13pt;text-align: left;">13. <b>McAuliffe JC</b>, <b>Hunt KK</b>, <b>Lazar AJ, et al. </b>(2009). A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumour cell apoptosis. <i>Annals of Surgical Oncology</i>, <b>16</b>(4): 910–919.</p><p class="nav">&nbsp;&nbsp;</p><p class="nav">&nbsp;</p><p class="nav"><a href="part16.htm">&lt; Назад</a><span> | </span><a href="../index.html">Содержимое</a><span> | </span><a href="part18.htm">Далее &gt;</a></p><p class="nav">&nbsp;&nbsp;</p></body></html>
